RT Journal Article
SR Electronic
T1 Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.24.21257753
DO 10.1101/2021.05.24.21257753
A1 Gladding, Patrick A.
A1 Young, Renee
A1 Cooper, Maxine
A1 Loader, Suzanne
A1 Smith, Kevin
A1 Zarate, Erica
A1 Green, Saras
A1 Villas-Boas, Silas G.
A1 Shepherd, Phillip
A1 Kakadiya, Purvi
A1 Thorstensen, Eric
A1 Keven, Christine
A1 Coe, Margaret
A1 Jüllig, Mia
A1 Zhang, Edmond
A1 Schlegel, Todd T.
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.05.24.21257753.abstract
AB Background Multiomics delivers more biological insight than targeted investigations. We applied multiomics to patients with heart failure with reduced ejection fraction (HFrEF).Methods 46 patients with HFrEF and 20 controls underwent metabolomic profiling, including liquid/gas chromatography mass spectrometry (LCMS/GCMS) and solid-phase microextraction (SPME) volatilomics in plasma and urine. HFrEF was defined using left ventricular global longitudinal strain, ejection fraction and NTproBNP. A consumer breath acetone (BrACE) sensor validated results in n=73.Results 28 metabolites were identified by GCMS, 35 by LCMS and 4 volatiles by SPME in plasma and urine. Alanine, aspartate and glutamate, citric acid cycle, arginine biosynthesis, glyoxylate and dicarboxylate metabolism were altered in HFrEF. Plasma acetone correlated with NT-proBNP (r = 0.59, 95% CI 0.4 to 0.7), 2-oxovaleric and cis-aconitic acid, involved with ketone metabolism and mitochondrial energetics. BrACE> 1.5 ppm discriminated HF from other cardiac pathology (AUC 0.8, 95% CI 0.61 to 0.92, P < 0.0001).Conclusion Breath acetone discriminated HFrEF from other cardiac pathology using a consumer sensor, but was not cardiac specific.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHealth Research Council of New Zealand Explorer Grant 16/680Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northern B Health and Disability Ethics Committee 16/NTB/115, 16/680 and Waitematā District Health Board IRB RM13458All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request